Polypharmacy in patients with epilepsy: A nationally representative cross-sectional study

202037 citationsJournal Articlehybrid Open Access

Authors

Samuel W. Terman · University of Michigan–Ann Arbor

Carole E. Aubert · VA Ann Arbor Healthcare System

Chloé E. Hill · University of Michigan–Ann Arbor

Donovan T. Maust · VA Ann Arbor Healthcare System

John P. Betjemann · University of California, San Francisco

Cynthia M. Boyd · Johns Hopkins University

James Burke

Abstract

Polypharmacy is common in patients with epilepsy. Patients taking ASMs frequently reported also taking other CNS-acting medications (i.e., opioids, benzodiazepines, seizure threshold-lowering medications), and medication combinations with black box warnings. Central nervous system polypharmacy poses health risks. Future research is needed to explore drivers of polypharmacy and strategies to help mitigate potentially harmful prescription use in this high-risk population.

Topics & Keywords

Epilepsy research and treatment Pharmacological Effects and Toxicity Studies Pharmaceutical Practices and Patient Outcomes

UN Sustainable Development Goals

Zero hunger

Publication Details

Published in: Epilepsy & Behavior

Volume 111, pp. 107261-107261

DOI: 10.1016/j.yebeh.2020.107261

Field-Weighted Citation Impact: 2.12